The Telangana government has unveiled its ambitious plan to attract $25 billion in investments in the life sciences sector over the next five years. This initiative is part of the Telangana Next-Gen Life Sciences Policy 2026–2030, with a goal to position the state among the top five global life sciences clusters by 2030. Chief Minister A. Revanth Reddy, along with a delegation, introduced the policy at the World Economic Forum in Davos.
Industry minister Sridhar Babu highlighted that the policy aims to generate 5 lakh new jobs and focus on high-value research and development, advanced biologics, and sustainable manufacturing practices. Key projects under this policy include the Green Pharma City, flagship Pharma Villages, and the 1Bio growth-phase center and biopharma manufacturing facility. Additionally, the government plans to establish a Life Sciences Innovation Fund of up to Rs 1,000 crore ($111 million).
Telangana, known for its significant contributions to India’s pharmaceutical industry, is strategically expanding into emerging fields like biologics and precision medicine. Leveraging its strengths in pharmaceutical manufacturing and vaccine production, the state aims to lead global life sciences innovation. With over 250 USFDA-approved manufacturing sites, Telangana is a key player in the pharmaceutical sector and has a substantial vaccine production capacity of about 14 billion doses.
The state has also gained recognition as a global vaccine hub and excels in the manufacturing of medical devices and diagnostic equipment. Telangana’s proactive approach in diversifying into new areas like biomanufacturing positions it as a frontrunner in healthcare and life sciences innovation on a global scale.
